MSH2 and non-small cell lung carcinoma: In patients with NSCLC treated with immune checkpoint inhibitors, responders with the highest TMB were found to have mutations in genes associated with DNA repair and replication, including the polymerase delta 1 catalytic subunit (POLD1), POLE, and MutS homolog 2 (MSH2) (Chae et al., 2018).